J&J Bets Up to $780 Million on Cidara’s Universal Influenza Treatment

J&J Bets Up to $780 Million on Cidara’s Universal Influenza Treatment

Source: 
BioSpace
snippet: 

Cidara Therapeutics inked a deal worth up to $780 million with Johnson & Johnson to develop and commercialize Cidara’s candidate CD388 for the prevention and treatment of seasonal and pandemic influenza.